Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy

Melanoma Research

Volumn 18, Issue 2, 2008, Pages 161-162

  Moncrieff, Marc ^a   Shannon, Kerwin ^a   Hong, Angela ^a   Hersey, Peter ^a   Thompson, John ^a  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

Author keywords

Lymphoedema; Melanoma; Sorafenib

Indexed keywords

HERBACEOUS AGENT; SERTRALINE; SORAFENIB;

ADULT; ALOPECIA; ANAMNESIS; ARTICLE; CANCER STAGING; CASE REPORT; DEPRESSION; DIARRHEA; DRUG WITHDRAWAL; FEMALE; HAND FOOT SYNDROME; HUMAN; LYMPHEDEMA; MELANOMA; NAUSEA; PERIPHERAL EDEMA; PRIORITY JOURNAL; TREATMENT OUTCOME; URTICARIA;

ADULT; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; FEMALE; HUMANS; LOWER EXTREMITY; LYMPHATIC METASTASIS; LYMPHEDEMA; MELANOMA; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 40849111494     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e3282f3d117     Document Type: Article

References (6)

1. Morabito A, De Maio E, Di Maio M, Normanno N, Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 2006; 11:753-764.
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al., TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356:125-134.
3. Haluska FG, Ibrahim N. Therapeutic targets in melanoma: map kinase pathway. Curr Oncol Rep 2006; 8:400-405.
4. Kalinsky K, Haluska FG. Novel inhibitors in the treatment of metastatic melanoma. Expert Rev Anticancer Ther 2007; 7:715-724.
5. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
6. Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 1995; 146:1029-1039.